2019 EULAR/ERA-EDTA 狼疮肾炎管理建议更新
该更新基于系统文献回顾与多学科工作组投票,修订了2012版狼疮肾炎管理建议,涉及治疗目标、糖皮质激素与钙调磷酸酶抑制剂的使用及终末期肾病管理。推荐以12个月内完全缓解为目标,活动性增殖性狼疮肾炎初始治疗采用霉酚酸酯或低剂量环磷酰胺联合糖皮质激素,后续以霉酚酸酯或硫唑嘌呤维持。
要点
- 治疗目标为12个月内完全缓解:尿蛋白<0.5-0.7 g/24h且肾小球滤过率接近正常。
- 活动性增殖性LN诱导治疗推荐MMF或低剂量静脉CY联合糖皮质激素。
- 维持治疗用MMF或硫唑嘌呤,糖皮质激素剂量<7.5 mg/d。
核心结论
- 更新了EULAR狼疮肾炎管理建议,推荐以12个月完全缓解为治疗目标,并明确了诱导与维持治疗方案。
研究设计与样本
- 遵循EULAR标准化操作流程进行系统文献回顾,由多学科工作组独立投票形成建议。
主要发现
- 治疗目标为12个月内完全缓解(尿蛋白<0.5-0.7 g/24h且肾小球滤过率接近正常),基线肾病范围蛋白尿者可延长。
- 活动性增殖性LN诱导治疗推荐MMF 2-3 g/天或等效MPA,或低剂量静脉CY 500 mg×6次双周,均联合糖皮质激素。
- 维持治疗推荐MMF或硫唑嘌呤,联用无或低剂量(<7.5 mg/天)糖皮质激素。
- 单纯膜性LN伴肾病范围蛋白尿或RAAS阻断后尿蛋白>1 g/24h者,优选MMF联合糖皮质激素。
- 终末期肾病患者肾替代治疗首选移植,免疫抑制依据移植方案和/或肾外表现决定。
关键数值与推荐
- 完全缓解目标:12个月时尿蛋白<0.5-0.7 g/24h且肾小球滤过率(接近)正常。
- 诱导方案:MMF 2-3 g/天或等效MPA,或静脉CY 500 mg×6次双周,联合静脉甲泼尼龙冲击后口服泼尼松0.3-0.5 mg/kg/天。
- 维持治疗糖皮质激素剂量:无或<7.5 mg/天。
- 单纯膜性LN治疗阈值:肾病范围蛋白尿或RAAS阻断后尿蛋白>1 g/24h。
临床怎么用
- 活动性增殖性LN初始治疗选择MMF或低剂量静脉CY联合糖皮质激素,维持治疗用MMF或硫唑嘌呤。
- 羟氯喹推荐使用并定期眼科监测。
- 治疗无应答时切换诱导方案或使用利妥昔单抗,不完全缓解或肾炎 flares 时重复肾活检。
- 儿童LN治疗原则与成人相同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To update the 2012 EULAR/ERA-EDTA recommendations for the management of lupus nephritis (LN). METHODS: Following the EULAR standardised operating procedures, a systematic literature review was performed. Members of a multidisciplinary Task Force voted independently on their level of agreeement with the formed statements. RESULTS: The changes include recommendations for treatment targets, use of glucocorticoids and calcineurin inhibitors (CNIs) and management of end-stage kidney disease (ESKD). The target of therapy is complete response (proteinuria <0.5-0.7 g/24 hours with (near-)normal glomerular filtration rate) by 12 months, but this can be extended in patients with baseline nephrotic-range proteinuria. Hydroxychloroquine is recommended with regular ophthalmological monitoring. In active proliferative LN, initial (induction) treatment with mycophenolate mofetil (MMF 2-3 g/day or mycophenolic acid (MPA) at equivalent dose) or low-dose intravenous cyclophosphamide (CY; 500 mg × 6 biweekly doses), both combined with glucocorticoids (pulses of intravenous methylprednisolone, then oral prednisone 0.3-0.5 mg/kg/day) is recommended. MMF/CNI (especially tacrolimus) combination and high-dose CY are alternatives, for patients with nephrotic-range proteinuria and adverse prognostic factors. Subsequent long-term maintenance treatment with MMF or azathioprine should follow, with no or low-dose (<7.5 mg/day) glucocorticoids. The choice of agent depends on the initial regimen and plans for pregnancy. In non-responding disease, switch of induction regimens or rituximab are recommended. In pure membranous LN with nephrotic-range proteinuria or proteinuria >1 g/24 hours despite renin-angiotensin-aldosterone blockade, MMF in combination with glucocorticoids is preferred. Assessment for kidney and extra-renal disease activity, and management of comorbidities is lifelong with repeat kidney biopsy in cases of incomplete response or nephritic flares. In ESKD, transplantation is the preferred kidney replacement option with immunosuppression guided by transplant protocols and/or extra-renal manifestations. Treatment of LN in children follows the same principles as adult disease. CONCLUSIONS: We have updated the EULAR recommendations for the management of LN to facilitate homogenization of patient care.
引用
- Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020. PMID: 32220834. doi:10.1136/annrheumdis-2020-216924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。